

STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ACE INHIBITOR(S)

Field of the Invention

5 The present invention relates to stable pharmaceutical compositions comprising
ace inhibitor(s), which are susceptible to degradation, and processes for the preparation
thereof.

Background

10 Certain Angiotensin Converting Enzyme (ACE)-inhibitors, which are useful as
antihypertensives, are susceptible to certain types of degradation. ACE inhibitors such as
ramipril, quinapril, enalapril, spirapril, lisinopril, benazepril and structurally related drugs
can undergo cyclization via internal nucleophilic attack to form substituted
diketopiperazines. These drugs can also degrade via hydrolysis (of the side-chain ester
15 group) and oxidation, to form products having unwanted coloration. It has been found that
a significant cause of such degradations can be the mechanical stress associated with the
manufacturing process of pharmaceutical composition such as compression. The stability
of pharmaceutical compositions containing ACE inhibitors can also be negatively
influenced by the choice of tableting auxiliaries. In view of the usefulness of ACE
20 inhibitors in treating hypertension, a number of research endeavors have been directed
towards overcoming the inherent instability problem associated with ACE inhibitor-
containing compositions.

For example United States Patent Nos. 4,743,450, 4,830,853, 4,793,998,
international patent application WO 99/62560, European patent EP 468929 disclose
25 stabilization with various agents. United States Patent Nos. 5,151,433 and 5,442,008
disclose polymeric film-formers as protection against stress, as well as the use of buffers.

Thus, either addition of a stabilizer or a polymeric coat on the active ingredient is
believed necessary to stabilize the pharmaceutical composition of ACE inhibitors, which
are susceptible to degradation. However, the addition of such stabilizers can produce
30 unwanted pharmacological effects. Coating the active ingredient is quite cumbersome and
low yielding moreover it requires specialized equipment.

Summary

The applicants of the present invention have discovered a process making the use of the above unnecessary. Active ingredient, for example, an ACE inhibitor, which is susceptible to degradation, is applied as a coat to the core, preferably to a compressed core, thereby avoiding degradation (such as cyclization to diketopiperazine) induced by mechanical stress, which builds up during compression. Such an arrangement also avoids the direct contact of the tableting auxiliaries with the ACE inhibitor, thereby avoiding degradation by any incompatible tablet auxiliaries.

The present invention therefore allows greater flexibility in the choice of tableting auxiliaries. Moreover, as stabilizers are not required, untoward pharmacological effects, which could occur with the addition of such additives, are nullified. The process can be easily scaled up using the conventional tableting and coating equipment.

Therefore, the present invention can provide a stable pharmaceutical composition for oral administration of an ACE inhibitor comprising a core coated with a layer of ACE inhibitor(s) and process for preparation thereof.

Detailed Description

The core of the present invention is preferably a compressed core, which could be inert or may contain a drug other than the ACE inhibitor susceptible to degradation, such as hydrochlorothiazide, piretanide; and dihydropyridines such as felodipine, nitrendipine, nifedipine, lacidipine or other similar drugs. Alternatively the core may be a sugar or starch particle such as non-pareil sugar seeds, or pregelatinized starch. The core can be of any convenient shape, such as an spheroidal shape. The cores can range from about 25 mg to about 1 gram.

The compressed core may comprise diluent and other formulating agents such as binder, disintegrant, lubricant and glidant. The diluent may be, for example, any pharmaceutically acceptable, non-toxic diluent. Particular examples include lactose, dextrose, sucrose, maltose, microcrystalline cellulose, starch, calcium hydrogen phosphate, mannitol and the like.

Binders may be, for example, starch, sugars, gums, low molecular weight hydroxypropyl methylcellulose, hydroxypropylcellulose or the like. Disintegrant may be, for example, croscarmellose sodium, crospovidone, sodium starch glycolate, bentonite, sodium alginate, hydroxypropylmethylcellulose or the like. Lubricants may be, for example, talc, magnesium stearate, calcium stearate, hydrogenated vegetable oils, stearic

acid, sodium stearyl fumarate, sodium benzoate or the like. Glidants may be, for example, colloidal silicon dioxide (aerosil), talc or the like.

The ACE inhibitor layer comprises ACE inhibitor(s), which are susceptible to degradation, including ramipril, spirapril, lisinopril, enalapril, quinapril, benazepril and other structurally related drugs. The process is applicable to other pharmaceutically active agents that are susceptible to mechanical stress-induced or mechanical stress-related degradation. The ACE inhibitor can be micronized, and suspended/dispersed in a solvent to which film forming polymer(s) is added. The film-forming polymer may be, for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, ethylcellulose, cellulose acetate, polyvinylpyrrolidone, gelatin, LustreClear™ (combination of microcrystalline cellulose and carrageenan), combinations of polyvinylalcohol and polyvinylacetate, and the like. The amount of the film forming polymer(s) can be relatively low, to limit the tablet/pellet/beadlet size and the manufacturing effort, but should be sufficient to effectively coat the drug on to the core. The drug to polymer ratio may range from about 1:10 to about 10:1. For example, drug to polymer ratio can be from about 1:2 to about 2:1, or from about 1:1.2 to about 1.2:1, or, for example, about 1:1.

The polymer that is used for binding properties can also protect ACE inhibitors from atmospheric or chemical oxidation and degradation by agents such as atmospheric humidity through, for example, hydrolysis.

The ACE inhibitor layer may optionally contain plasticizers, and is desirably without plasticizers. Stability can be undesirably lessened through the use of plasticizers. Plasticizers which may be excluded from the compositions include polyethyleneglycol, propylene glycol, triethyl citrate, triacetin, dibutylphthalate, diethylphthalate, castor oil, tributyl citrate, glycerol, sorbitol, polysorbates, sorbitan esters and the like. The ACE inhibitor layer may also contain pigments, colorants, antifoaming agents, waxes, monoglycerides, emulsifiers, surfactants or other additives. The layer containing ACE inhibitor or other pharmaceutically active substance can contain such material from about 2% to about 90% by weight of the ACE inhibitor layer, and can also contain film-forming polymer from about 10% to about 98% by weight of the ACE inhibitor layer.

Drug coating solution can be prepared in water, non-aqueous solvents or mixtures thereof. However desirably in water as stability can be lessened through the use of non-aqueous solvents. Solvents that may be excluded are isopropyl alcohol, acetone and methylene chloride.

A seal coat may optionally separate the core and the ace inhibitor layer to completely seal the tableting auxiliaries to come in contact with the ACE inhibitor. Similarly, an outer coat may optionally be given on the ACE inhibitor layer to improve the aesthetic appeal of the tablet and to protect it from the atmospheric humidity. The seal
5 coat and outer coat may have the same composition as the ACE inhibitor layer except the drug, or it may have a different composition. For example, the seal coat may contain other polymers, such as Povidone. The seal coat can be prepared from aqueous dispersion of from about 2% to about 30% by weight of film-forming polymer.

The process of the present invention may be carried out in the following manner.

10 The compressed core can be prepared by conventional techniques such as direct compression, wet granulation and dry granulation.

The ACE inhibitor coating dispersion, suspension or solution can be prepared by adding the active ingredient(s) in a solvent with stirring or other mixing. Film forming polymer(s) and other additives can be added to the active ingredient dispersion with
15 stirring or other mixing. The cores are charged into a coating pan and warmed with air to an outlet-air temperature of, for example, about 30°C-45°C. The ACE inhibitor coating dispersion can be sprayed onto the cores and upon completion, the drug-coated tablets is dried, for example with dry air. Seal coat and outer coat dispersion may be prepared and applied in the similar manner as the ACE inhibitor layer, if required.

20 The coated tablets after air-drying can be packed into containers impervious to water vapor, e.g. blister packs (alu-alu; PVDC, PE, PVC-alu).

The tablets prepared by the present process may also be filed into capsules. The present process may also be applied to the non-pareil seeds or beadlets, which may then be filled in hard gelatin or starch capsules. Such capsules can have better stability as
25 compared to the conventional capsules.

The compositions disclosed herein may be formulated into solid dosage forms for oral administration, such as, for example, tablets, granules, capsules, pills, and the like. In these cases, the medicaments can be prepared by conventional methods, including a therapeutically effective amount of an ACE inhibitor or other pharmaceutically active
30 substance, and optionally but desirably, pharmaceutically acceptable excipients. In addition to the common dosage forms set out, the compositions may also be administered by controlled release means and/or delivery devices, with modifications known to those of ordinary skill in the art.

The compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

5 By "therapeutically effective amount" is meant the quantity of a compound or composition according to the invention necessary to prevent, cure or at least partially arrest the symptoms of the disorder and its complications. Amounts effective to achieve this goal will, of course, depend on the severity of the disease and the weight and general state of the patient.

10 Methods of Treatment

The pharmaceutical compositions provided herein can be utilized for various treatment methods, such as those for treating hypertension, either alone or in combination with thiazide diuretics, as well as for use with stable patients who have demonstrated
15 clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction, and also for left ventricular dysfunction and diabetic nephropathy.

The methods include administering to a mammal a therapeutically effective amount of a pharmaceutical composition as described herein.

The administration of pharmaceutical compositions can be by oral or buccal
20 administration,. Other methods of administration will be known to those skilled in the art.

Using the process parameters of the present invention, a convenient, reproducible stable pharmaceutical composition of the ACE inhibitors may be obtained. The present invention is further illustrative by, but is by no-means limited to, the following examples.

25 Examples

Example 1: Preparation of ACE inhibitor formulation

To prepare the tablet cores, in a non-shear blender, microcrystalline cellulose, Pregelatinised starch & Mannitol were mixed and to this mixture sodium stearyl fumarate was added and mixed. The mixture is then compressed to tablets of 100 mg each.

30 To prepare the seal coating solution, hydroxypropylmethylcellulose, hydroxypropylcellulose,(polyethylene glycol, titanium dioxide, and talc) were dispersed in water with stirring and the suspension homogenized.

To prepare the drug coating suspension, ramipril was dispersed in water with stirring and to it hydroxypropylmethylcellulose, hydroxypropylcellulose, (polyethylene glycol, titanium dioxide, and talc) were added. The suspension was homogenized.

The outer-coating solution was prepared similar to the seal coat solution.

5 Tablet cores were placed in the coating pan (Hi-Coater) and heated with warm air to an air outlet temperature of about 30°C-45°C. The seal coating solution was sprayed on the cores. Upon completion the heating was discontinued but the air supply was maintained for about 10 minutes in order to dry the tablets.

10 The coated cores were sprayed with the drug coating solution and air dried maintaining the process parameters as for the seal coat. Similarly, the outer coating solution was then sprayed on the drug coated cores. The tablets were air dried and extracted from the apparatus and packed in suitable pack. The particular amounts of ingredients for various formulations are tabulated in Tables I, II III, IV and V. Tablets prepared according to the ingredients of these tables were prepared according to the
15 process described above.

Table I

INGREDIENT	WEIGHT(mg)
Core	
Mannitol	44.50
Microcrystalline cellulose	43.50
Pregelatinised starch	10.0
Sodium Stearyl Fumarate USNF	2.0
Tablet Weight	100.00
Seal Coat	2
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Target Weight	102.00
Drug layer	
Ramipril	2.5
Film forming Polymer	2.5
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Target Weight	107.00
Outer Coat	2.0
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Total Weight	109.00

Table II

INGREDIENT	WEIGHT(MG)
Core	
Hydrochlorothiazide	25.0
Mannitol	40.0
Dibasic Calcium Phosphate (Anhydrous)	97.855
Starch	19.60
Pregelatinized Starch	4.4
Ferric Oxide (Red)	0.165
Ferric Oxide (Yellow)	0.33
Purified Water	q.s
Pregelatinised Starch	11.00
Magnesium Stearate	1.65
Tablet Weight	200.00
Seal Coat	4.00
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Target Weight	204.00
Drug layer	
Ramipril	5.0
Film forming Polymer	5.0
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Target Weight	214.00
Outer Coat	4.00
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Total Weight	218.00

Table III

INGREDIENT	WEIGHT(MG)
Core	
Mannitol	44.50
Microcrystalline cellulose	43.50
Pregelatinised starch	10.0
Sodium Stearyl Fumarate USNF	2.0
Tablet Weight	100.00
Seal Coat	2
Hydroxypropylmethylcellulose	
Purified water (q.s)	
Target Weight	102.00
Drug layer	
Ramipril	2.5
Hydroxypropylmethylcellulose	2.5
Purified water (q.s)	q.s
Target Weight	107.00
Outer Coat	2.0
Hydroxypropylmethylcellulose	
Purified water (q.s)	
Total Weight	109.00

Table IV

INGREDIENT	WEIGHT (MG)
Core tablets:	
Mannitol	44.50
Microcrystalline cellulose	44.50
Pregelatinized starch	10.0
Sodium Stearyl Fumarate	1.0
Tablet Weight	100.0
Pre Coat	
Hydroxypropylmethyl cellulose	2.50
Purified water	q.s
Target Weight	102.0
Drug layer	
Ramipril	3.28
Hydroxypropylmethyl cellulose	2.98
Hydroxypropyl Cellulose	0.3
Purified water	q.s
Target Weight	107.25

Table V

Ingredients	Qty(mg)
Core tablets:	
Hydrochlorothiazide	12.50
Mannitol	20.0
Dibasic Calcium Phosphate (anhydrous)	48.928
Maize Starch	9.80
Pregelatinized Starch	2.20
Ferric Oxide (Red)	0.0825
Ferric Oxide (Yellow)	0.165
Purified Water	q.s
Pregelatinised Starch	5.50
Magnesium Stearate	0.825
Tablet Weight	100.00
Pre Coat 1	
Hydroxypropylmethyl cellulose	1.8125
Hydroxypropyl Cellulose	0.1875
Titanium Dioxide	0.50
Purified water	q.s.
Target Weight	102.0
Pre Coat 2	
Hydroxypropylmethyl cellulose	2.5
Purified water	q.s
Target Weight	104.0
Drug layer	
Ramipril	3.28
Hydroxypropylmethyl cellulose	2.98
Hydroxypropyl Cellulose	0.30
Purified water	q.s
Target Weight	109.25

Stability comparisons with conventional tablets having ramipril in the core with or
5 without buffer and marketed ramipril tablets (Delix) of Aventis are shown in Table VI
below.

**TABLE VI: Stability Comparison of 2.5-mg Ramipril Tablets
Prepared by Different Composition/Techniques**

Degradation product	Condition	Ramipril tablets			
		Conventional compressed tablet	Compressed tablet with tris-(hydroxymethyl) aminomethane buffer	Tablets prepared as per example 1	Delix marketed ramipril tablets of Aventis
Diketopiperazine (%)	Initial	1.91	0.048	0.262	
	60°C/2 weeks	18.48	4.61	4.42	5.91
Total Related Substances (%)	Initial	1.95	0.072	0.47	
	60°C/2 weeks	19.22	7.26	4.59	

The stability of tablets prepared according to Tables IV and V was determined at 40°C / 75% relative humidity for a period of 6 months. The results of the same are summarized in Table VII and VIII below.

**Table VII: Stability Data of Ramipril Tablets Prepared as per Table IV
for 6 Months Stored at 40°C/75% Relative Humidity**

	Initial	1 month	2 months	3 months	6 months
Diketopiperazine (%)	0.13	1.26	1.92	2.88	4.92
Total impurities (%)	0.16	1.48	2.06	3.19	5.51
Assay (%w/w)	103.2	101.6	99.3	98.1	95.4

Table VIII: Stability Data of Ramipril+Hydrochlorothiazide Tablets Prepared as per Table V for 6 Months Stored at 40°C/75% Relative Humidity

	Initial	1 month	2 months	3 months	6 months
Diketopiperazine (%)	0.265	1.448	2.295	3.481	6.778
Impurities of Hydrochlorothiazide (%)	0.407	0.436	0.531	0.701	0.829
Total Impurities (%)	1.289	2.573	3.094	4.338	7.159
Assay (%w/w)					
Ramipril Assay (%)	103.8	102.6	100.4	97.2	93.8
Hydrochlorothiazide assay (%)	101.2	101.3	100.8	100.6	99.2

- 5 The data clearly show that the tablets prepared by the processes described herein provide the most stable tablets.

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.